JPMorgan initiates Neurogene stock rating at Overweight on gene therapy potential
Covered in this story
Tracked from this story
JPMorgan’s $60 target on $NGNE is on the record and being tracked to Oct 2027 (12-month default), scored on the close that day.
JPMorgan’s track record →Call it yourself
No member calls on $NGNE yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Neurogene Inc →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.